ClinicalTrials.gg
RecruitingNCT03286686PPCfonctionsUpdated Jan 20, 2026

Sensori-motor and Perceptual Functions of the PPC.

An interventional study of point targets and tactile stimulation in Healthy Volunteers and Optic Ataxia, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Feb 2018; still recruiting 8 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To produce hand's movement directed towards a target, the investigator must combine several sensory information, such as vision or proprioception. The posterior parietal cortex (PPC) is a region of the cortex involved in this multisensory integration. A lesion of the PPC cause a visuo-motor trouble called optic ataxia but these patients also have perceptual troubles.

The aim of the study is to understand the different functions of the PPC and especially how the processes of spatial coding of the sensory information influences perception and motor planning.

In this study, the investigator want to explore the sensory motor and the perceptual performance of patients with optic ataxia compared with healthy subjects, using 6 behavioral tests.

Objectify the consequences of PPC impairment (visual-motor and perceptual consequences) on patients' quality of life and autonomy.

02

Conditions studied

  • Healthy Volunteers
  • Optic Ataxia

Browse trials for

Keywords

  • optic ataxia
  • posterior parietal cortex functions
  • multisensory integration
03

In context

Ataxia

149 studies on the registry are indexed under Ataxia; 37 are open to participants now.

This study's planned enrollment of 160 is above the median of 30 across 100 interventional studies indexed under Ataxia.

Browse Ataxia studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients and healthy subjects:

  • male and female, age from 18 to 75 years included
  • normal vision or corrected vision
  • covered by social security
  • signed written

Patients:

  • neurological injury in posterior parietal cortex supported by a cerebral MRI
  • present optic ataxia symptoms Healthy subjects
  • no known neurological injury

Exclusion criteria

Exclusion Criteria:

- unable to comply with the tasks (neurological, psychiatric, sensory or motor troubles)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Experience 1

    Behavioral: point targets

  • Experimental
    Experience 2

    Behavioral: point targets

  • Experimental
    Experience 3

    Behavioral: tactile stimulation

  • Experimental
    Experience 4

    Behavioral: visual images

  • Experimental
    Experience 5

    Behavioral: visual images

  • Experimental
    Experience 6

    Behavioral: visual images

Interventions

  • Behavioralpoint targets

    In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.

  • Behavioraltactile stimulation

    In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.

  • Behavioralvisual images

    Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.

06

What researchers measure

Primary outcomes

  1. response error - number of pointing error

    Time frame: Day 0 after each stimulation

  2. response error -measure of reaction times

    Time frame: Day 0 after each stimulation

  3. response error - percentage of right responses

    Time frame: Day 0 after each stimulation

07

Study locations

1 of 1 sites recruiting
  • U1028 INSERM - CNRS UMR 5292 Equipe ImpAct
    Bron, 69500, France
    Recruiting
    • Laure Pisella, PhD · Contactlaure.pisella@inserm.fr · 4 72 91 34 05
    • Laure Pisella, PhD · Principal investigator
    • Sophie JACQUIN-COURTOIS, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03286686
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Feb 22, 2018
Primary completion
Feb 22, 2031 (estimated)
Completion
Feb 22, 2031 (estimated)
Last update
Jan 20, 2026

Study contacts

Laure PISELLA, PhD
Contact
laure.pisella@inserm.fr
4 72 91 34 05 ext. +33
Laure PISELLA, PhD
principal investigator · INSERM U1028 - Impact - CRNL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion